CIK 1687078
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 95.86% | 38 |
| Unclassified | 2.70% | 2 |
| Health Care Providers & Services | 1.44% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DBVT | DBV Technologies S.A. | Health Care | 8.41% |
| 2 | CGEM | Cullinan Therapeutics, Inc. | Health Care | 8.39% |
| 3 | AKTS | Aktis Oncology, Inc. | Health Care | 6.68% |
| 4 | LQDA | Liquidia Corp | Health Care | 4.10% |
| 5 | ALMS | ALUMIS INC. | Health Care | 4.06% |
| 6 | EWTX | Edgewise Therapeutics, Inc. | Health Care | 4.04% |
| 7 | RVMD | Revolution Medicines, Inc. | Health Care | 3.81% |
| 8 | AGIO | AGIOS PHARMACEUTICALS, INC. | Health Care | 3.41% |
| 9 | CORT | CORCEPT THERAPEUTICS INC | Health Care | 3.07% |
| 10 | TRVI | Trevi Therapeutics, Inc. | Health Care | 3.04% |
39/41 names classified · sector 97.3% of weight · industry 97.3% · mkt cap 87.4%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 97.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 3% of book weight classified — the grid is NOT representative of the whole book.
Classified: 3.1% of book weight (1/41 names) · unclassified 96.9%: DBVT, CGEM, AKTS, LQDA, ALMS, EWTX, RVMD, AGIO, TRVI, DNTH +30 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DBVTDBV TECHNOLOGIES S A | 5,213,361 | $109M | 8.4% | ADD 423% |
| 2 | CGEMCULLINAN THERAPEUTICS INC | 7,648,268 | $109M | 8.4% | HOLD |
| 3 | AKTSAKTIS ONCOLOGY INC | 4,835,872 | $87M | 6.7% | NEW |
| 4 | LQDALIQUIDIA CORPORATION | 1,405,158 | $53M | 4.1% | HOLD |
| 5 | ALMSALUMIS INC | 2,386,529 | $53M | 4.1% | HOLD |
| 6 | EWTXEDGEWISE THERAPEUTICS INC | 1,660,696 | $52M | 4.0% | HOLD |
| 7 | RVMDREVOLUTION MEDICINES INC | 506,776 | $49M | 3.8% | HOLD |
| 8 | AGIOAGIOS PHARMACEUTICALS INC | 1,306,261 | $44M | 3.4% | HOLD |
| 9 | CORTCORCEPT THERAPEUTICS INC | 985,700 | $40M | 3.1% | NEW |
| 10 | TRVITREVI THERAPEUTICS INC | 3,298,430 | $39M | 3.0% | HOLD |
| 11 | DNTHDIANTHUS THERAPEUTICS INC | 423,982 | $36M | 2.7% | NEW |
| 12 | XENEXENON PHARMACEUTICALS INC | 588,706 | $34M | 2.6% | ADD 21% |
| 13 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 1,811,082 | $34M | 2.6% | NEW |
| 14 | TVTXTRAVERE THERAPEUTICS INC | 1,133,365 | $34M | 2.6% | NEW |
| 15 | EVMNEVOMMUNE INC | 1,455,863 | $33M | 2.6% | ADD 1188% |
| 16 | CYTKCYTOKINETICS INC | 500,000 | $33M | 2.5% | NEW |
| 17 | SNDXSYNDAX PHARMACEUTICALS INC | 1,340,733 | $31M | 2.4% | HOLD |
| 18 | CNTXCONTEXT THERAPEUTICS INC | 10,679,391 | $28M | 2.2% | HOLD |
| 19 | FBRXFORTE BIOSCIENCES INC | 1,000,682 | $26M | 2.0% | NEW |
| 20 | PVLAPALVELLA THERAPEUTICS INC | 206,404 | $26M | 2.0% | HOLD |
| 21 | DYNDYNE THERAPEUTICS INC | 1,408,152 | $26M | 2.0% | HOLD |
| 22 | STOKSTOKE THERAPEUTICS INC | 767,038 | $25M | 1.9% | HOLD |
| 23 | CRVSCORVUS PHARMACEUTICALS INC | 1,674,875 | $25M | 1.9% | TRIM −39% |
| 24 | RLAYRELAY THERAPEUTICS INC | 2,359,586 | $23M | 1.8% | ADD 6% |
| 25 | TARSTARSUS PHARMACEUTICALS INC | 329,750 | $23M | 1.8% | HOLD |
| 26 | ORICORIC PHARMACEUTICALS INC | 1,803,945 | $23M | 1.8% | HOLD |
| 27 | QUREUNIQURE NV | 1,369,231 | $22M | 1.7% | HOLD |
| 28 | GLUEMONTE ROSA THERAPEUTICS INC | 1,176,928 | $19M | 1.5% | HOLD |
| 29 | NTRANATERA INC | 93,074 | $19M | 1.4% | HOLD |
| 30 | CLYMCLIMB BIO INC | 2,593,439 | $18M | 1.4% | TRIM −3% |
| 31 | ARQTARCUTIS BIOTHERAPEUTICS INC | 733,966 | $17M | 1.3% | ADD 38% |
| 32 | URGNUROGEN PHARMA LTD | 943,803 | $17M | 1.3% | HOLD |
| 33 | DRUGBRIGHT MINDS BIOSCIENCES INC | 212,175 | $15M | 1.2% | TRIM −8% |
| 34 | ZYMEZYMEWORKS INC | 565,249 | $14M | 1.1% | NEW |
| 35 | BLTEBELITE BIO INC | 88,045 | $14M | 1.1% | HOLD |
| 36 | VRDNVIRIDIAN THERAPEUTICS INC | 649,873 | $13M | 1.0% | NEW |
| 37 | ENGENE HOLDINGS INC | 1,845,373 | $13M | 1.0% | HOLD |
| 38 | ABVXABIVAX SA | 107,268 | $12M | 0.9% | ADD 90% |
| 39 | ALLOALLOGENE THERAPEUTICS INC | 2,242,933 | $5M | 0.4% | NEW |
| 40 | ACRSACLARIS THERAPEUTICS INC | 391,918 | $1M | 0.1% | NEW |
| 41 | HOWLWEREWOLF THERAPEUTICS INC | 1,208,810 | $1M | 0.1% | TRIM −13% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DBVTDBV TECHNOLOGIES S A | — | — | 1.1M | 1.1M | 997K | 5.2M | $109M |
| CGEMCULLINAN THERAPEUTICS INC | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | $109M |
| AKTSAKTIS ONCOLOGY INC | — | — | — | — | — | 4.8M | $87M |
| LQDALIQUIDIA CORPORATION | — | — | — | 200K | 1.4M | 1.4M | $53M |
| ALMSALUMIS INC | — | — | — | — | 2.4M | 2.4M | $53M |
| EWTXEDGEWISE THERAPEUTICS INC | 1.1M | 1.1M | 1.7M | 1.7M | 1.7M | 1.7M | $52M |
| RVMDREVOLUTION MEDICINES INC | 314K | 317K | 316K | 316K | 506K | 507K | $49M |
| AGIOAGIOS PHARMACEUTICALS INC | — | — | — | — | 1.3M | 1.3M | $44M |
| CORTCORCEPT THERAPEUTICS INC | — | — | — | — | — | 986K | $40M |
| TRVITREVI THERAPEUTICS INC | 3.1M | 3.4M | 3.4M | 3.4M | 3.3M | 3.3M | $39M |
| DNTHDIANTHUS THERAPEUTICS INC | — | — | — | — | — | 424K | $36M |
| XENEXENON PHARMACEUTICALS INC | 197K | 303K | 323K | 503K | 486K | 589K | $34M |
| MLTXMOONLAKE IMMUNOTHERAPEUTICS | 315K | 316K | 314K | — | — | 1.8M | $34M |
| TVTXTRAVERE THERAPEUTICS INC | — | — | — | — | — | 1.1M | $34M |
| EVMNEVOMMUNE INC | — | — | — | — | 113K | 1.5M | $33M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
